Research analysts at Canaccord Genuity boosted their target price on shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) from $36.00 to $44.00 in a report released on Thursday.

The analysts wrote, “On the Q4 EPS call, AEGR provided metrics on the first six weeks of the Juxtapid launch in HoFH. The key takeaway was 400+ vs. 1800-targeted U.S. physicians have been REMS-trained (expected to translate into scripts 1-8 weeks post) and have written 85 new scripts globally (“vast majority” in the U.S. – Brazil and Turkey may be active on a named-patient basis). Given the strong early launch progress, we question whether guidance of 250-300 patients on drug exiting 2013 and $15M-25M in 2013 revenue is conservative.”

Shares of Aegerion Pharmaceuticals traded down 1.69% during mid-day trading on Thursday, hitting $35.51. Aegerion Pharmaceuticals has a 52 week low of $11.75 and a 52 week high of $37.10. The stock’s 50-day moving average is currently $28.72. The company’s market cap is $904.7 million.

AEGR has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase raised their price target on shares of Aegerion Pharmaceuticals to $39.00 in a research note to investors on Thursday. Separately, analysts at Bank of America raised their price target on shares of Aegerion Pharmaceuticals to $42.00 in a research note to investors on Thursday. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They now have a $41.00 price target on the stock, up previously from $37.00.

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.